Choline Salicylate is a non-steroidal anti-inflammatory drug (NSAID) and a salicylate ester, combining choline with salicylic acid. It acts as a potent analgesic, antipyretic, and anti-inflammatory agent. In the Indian market, it is primarily formulated as a topical gel or liniment for localized pain relief, offering the advantage of direct application with minimal systemic absorption and reduced risk of gastrointestinal side effects compared to oral salicylates.
Adult: Apply a thin layer to the affected area 3 to 4 times daily. Gently rub in. The amount should be sufficient to cover the area without excessive application. Wash hands after application unless treating hands.
Note: For external use only. Apply to clean, dry, intact skin. Do not apply on broken skin, open wounds, mucous membranes, eyes, or eczematous areas. Do not use with occlusive dressings unless directed by a physician. Do not apply heat (heating pads) over the area.
Choline Salicylate exerts its effects primarily through its salicylate component. It acts by irreversibly inhibiting cyclooxygenase (COX) enzymes, COX-1 and COX-2, thereby blocking the conversion of arachidonic acid to prostaglandins (PGs) and thromboxanes. This inhibition reduces the synthesis of inflammatory mediators (PGE2, PGI2) at the site of application, leading to decreased pain, swelling, and fever. It may also inhibit neutrophil activation and migration.
Pregnancy: Category D (Third Trimester). Avoid in first and second trimesters unless clearly needed. In third trimester, it may cause premature closure of ductus arteriosus, delayed labor, and increased risk of maternal and neonatal bleeding. Topical use is preferred over oral if necessary, but systemic absorption can occur.
Driving: Unlikely to affect driving ability when used topically. However, systemic absorption causing dizziness, vertigo, or tinnitus may impair alertness.
| Warfarin, Acenocoumarol | Increased risk of bleeding due to additive antiplatelet effect and potential displacement from protein binding sites. | Major |
| Methotrexate | Decreased renal clearance of methotrexate, leading to increased toxicity (myelosuppression). | Major |
| Other Oral NSAIDs (e.g., Ibuprofen, Diclofenac) | Increased risk of gastrointestinal side effects and renal toxicity without added therapeutic benefit. | Moderate |
| ACE Inhibitors (e.g., Enalapril, Ramipril) | Attenuated antihypertensive effect; potential worsening of renal function. | Moderate |
| Diuretics (e.g., Furosemide) | Reduced diuretic and antihypertensive efficacy; risk of nephrotoxicity. | Moderate |
| Lithium | Increased serum lithium levels and risk of toxicity due to reduced renal clearance. | Major |
| Sulfonylureas (e.g., Glimepiride) | Enhanced hypoglycemic effect. | Moderate |
| Valproic Acid | Displacement from protein binding, leading to increased free valproate levels and potential toxicity. | Moderate |